Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 2/20 | 0.47 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.47 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.47 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.47 |
| ▸ | CNR1 | P21554 | 2/20 | 0.47 |
| ▸ | CNR2 | P34972 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | FASN | P49327 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7057555 | 1.00 | PRKCA (0.47) | PRKCAPRKCEPRKCQPRKCDCNR1 | |
| SCHEMBL9641260 | 1.00 | PRKCA (0.47) | PRKCAPRKCEPRKCQPRKCDCNR1 | |
| SCHEMBL9641266 | 1.00 | PRKCA (0.47) | PRKCAPRKCEPRKCQPRKCDCNR1 | |
| SCHEMBL30135618 | 0.93 | PRKCA (0.56) | PRKCAPRKCEPRKCQPRKCDCNR1 | |
| SCHEMBL6023068 | 0.93 | PRKCA (0.56) | PRKCAPRKCEPRKCQPRKCDCNR1 | |
| SCHEMBL9405398 | 0.92 | PRKCA (0.57) | PRKCAPRKCEPRKCQPRKCDCNR1 | |
| SCHEMBL19612935 | 0.92 | PRKCA (0.55) | PRKCAPRKCEPRKCQPRKCDCNR1 | |
| SCHEMBL17713798 | 0.92 | PRKCA (0.55) | PRKCAPRKCEPRKCQPRKCDCNR1 | |
| SCHEMBL317317 | 0.92 | PRKCA (0.55) | PRKCAPRKCEPRKCQPRKCDCNR1 | |
| SCHEMBL17713799 | 0.92 | PRKCA (0.55) | PRKCAPRKCEPRKCQPRKCDCNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12213956-B2 | Method of treating fatty acid oxidation disorders using omega3/omega6 unsaturated or branched chain fatty acids | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2025-02-04 | — | — | US | disclosed |
| US-11844775-B2 | Method of treating fatty acid oxidation disorders using Omega3/Omega6 unsaturated or branched chain fatty acids | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2023-12-19 | — | — | US | disclosed |
| US-20210353581-A1 | Method of Treating Fatty Acid Oxidation Disorders Using Omega3/Omega6 Unsaturated or Branched Chain Fatty Acids | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2021-11-18 | — | — | US | disclosed |
| US-20210322357-A1 | Method of Treating Fatty Acid Oxidation Disorders Using Omega3/Omega6 Unsaturated or Branched Chain Fatty Acids | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2021-10-21 | — | — | US | disclosed |
| US-20030032674-A1 | Use of unsaturated fatty acids to treat severe inflammatory diseases | BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE | 2003-02-13 | — | — | US | disclosed |
| US-5874470-A | CONTAINING EICOSAPENTAENOIC ACID AS A COMPONENT OF FISH OIL, MEDIUM CHAIN TRIGLYCERIDES CONTAINING 90% CAPRYLIC AND/OR CAPRIC ACID TRIGLYCERIDES, A PHOSPHOLIPID EMULSIFIER, A LINOLEIC ACID AS A COMPONENT OF SOYBEAN OR SAFFLOWER OIL | B. BRAUN MELSUNGEN AG (DE) | 1999-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210353581-A1 | Method of Treating Fatty Acid Oxidation Disorders Using Omega3/Omega6 Unsaturated or Branched Chain Fatty Acids | ELOVL6, ELOVL3, CPT1B | PRKCA 1423/4885PRKCE 1856/4885PRKCQ 1696/4885 |
| US-11844775-B2 | Method of treating fatty acid oxidation disorders using Omega3/Omega6 unsaturated or branched chain fatty acids | ELOVL6, ELOVL3, CPT1B | PRKCA 1470/4885PRKCE 1921/4885PRKCQ 1764/4885 |
| US-20210322357-A1 | Method of Treating Fatty Acid Oxidation Disorders Using Omega3/Omega6 Unsaturated or Branched Chain Fatty Acids | ELOVL6, ELOVL3, CPT1B | PRKCA 1470/4885PRKCE 1921/4885PRKCQ 1764/4885 |
| US-12213956-B2 | Method of treating fatty acid oxidation disorders using omega3/omega6 unsaturated or branched chain fatty acids | ELOVL6, ELOVL3, CPT1B | PRKCA 1423/4885PRKCE 1856/4885PRKCQ 1696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.